You are here

lung cancer

Upcoming events – Axsome’s depression data and Eli Lilly’s IL-10 in lung cancer

Upcoming events – Axsome’s depression data and Eli Lilly’s IL-10 in lung cancer

EP Vantage

Axsome Therapeutics

treatment-resistant depression

Flag link:

Regeneron defends bid to challenge Merck in lung cancer

Regeneron defends bid to challenge Merck in lung cancer

Biopharma Dive

immuno-oncology

Flag link:

Should Merck Investors Worry About Bristol Myers' Lung Cancer Drug Results?

Should Merck Investors Worry About Bristol Myers' Lung Cancer Drug Results?

Motley Fool

Bristol-Myers Squibb

Flag link:

Triple meeting – Mirati avoids the worst-case scenario

Triple meeting – Mirati avoids the worst-case scenario

EP Vantage

Mirati Therapeutics

colorectal cancer

Flag link:

Lilly touts Cyramza lung cancer data, as AZ’s Tagrisso grows even more powerful

Lilly touts Cyramza lung cancer data, as AZ’s Tagrisso grows even more powerful

Fierce Pharma

EGFR lung cancer

Flag link:

Researchers Develop New Class of Lung Cancer Drugs

Researchers Develop New Class of Lung Cancer Drugs

BioSpace

KRAS inhibitors

Institute of Cancer Research

drug development

Flag link:

Merck KGaA nabs FDA “Breakthrough” tag for MET-targeting lung cancer drug

Merck KGaA nabs FDA “Breakthrough” tag for MET-targeting lung cancer drug

Pharmaforum

non-small cell lung cancer

Flag link:

At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More

At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More

Xconomy

Blueprint Medicines

Flag link:

Rova-T: the story of AbbVie’s multi-billion dollar failure

Rova-T: the story of AbbVie’s multi-billion dollar failure

Pharmaforum

Flag link:

Mylan's Newly-Approved Alimta Generic Will Not be Sold Until 2022

Mylan's Newly-Approved Alimta Generic Will Not be Sold Until 2022

BioSpace

Flag link:

3 Lung Cancer Stocks That Could Soar in September

3 Lung Cancer Stocks That Could Soar in September

Motley Fool

Flag link:

Amgen results beat estimates, lung cancer trial planned

Amgen results beat estimates, lung cancer trial planned

Yahoo/Reuters

clinical trials

Flag link:

AstraZeneca spearheads lung cancer alliance aiming to boost survival rates

AstraZeneca spearheads lung cancer alliance aiming to boost survival rates

Fierce Pharma

Lung Ambition Alliance

Flag link:

Biodesix Looks to Become ‘the’ Lung Cancer Detection Co. With New Acquisition

Biodesix Looks to Become ‘the’ Lung Cancer Detection Co. With New Acquisition

Medical Devices and Diagnostics Industry

Flag link:

Spotlight on: Exosome Diagnostics, first to develop RNA-based liquid biopsies

Spotlight on: Exosome Diagnostics, first to develop RNA-based liquid biopsies

CP Wire

Exosome Diagnostics

prostate cancer

Flag link:

Spotlight on: Exosome Diagnostics, first to develop RNA-based liquid biopsies

Exosome Diagnostics

prostate cancer

Flag link:

Did This Biotech Giant Just Find The Key To An 'Undruggable' Protein?

Did This Biotech Giant Just Find The Key To An 'Undruggable' Protein?

Investors Business Daily

Flag link:

Early cancer drug data give Amgen hope it's 'cracked KRAS code'

Early cancer drug data give Amgen hope it's 'cracked KRAS code'

Biopharma Dive

colorectal cancer

pancreatic cancer

Flag link:

For some lung cancer patients, Keytruda provides lasting benefit

For some lung cancer patients, Keytruda provides lasting benefit

Biopharma Dive

Flag link:

Google’s AI improves accuracy of lung cancer diagnosis, study shows

Google’s AI improves accuracy of lung cancer diagnosis, study shows

Stat

artificial intelligence

Flag link:

Pages